Halozyme Therapeutics, Inc. $HALO Shares Sold by Swedbank AB

Swedbank AB lowered its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,162 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the period. Swedbank AB’s holdings in Halozyme Therapeutics were worth $10,793,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HALO. Newbridge Financial Services Group Inc. acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at $32,000. Employees Retirement System of Texas purchased a new stake in shares of Halozyme Therapeutics in the second quarter worth about $34,000. Asset Management One Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $98,000. EverSource Wealth Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares during the period. Finally, ST Germain D J Co. Inc. acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $142,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the subject of several recent research reports. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Benchmark upped their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Friday, December 19th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Hold” and an average price target of $75.10.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $71.60, for a total value of $59,356.40. Following the completion of the sale, the director directly owned 42,123 shares in the company, valued at approximately $3,016,006.80. The trade was a 1.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 16,569 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $48,844,913.48. This represents a 2.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 85,661 shares of company stock valued at $6,036,837 over the last three months. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Trading Up 0.7%

NASDAQ HALO opened at $68.87 on Friday. The company has a market capitalization of $8.10 billion, a price-to-earnings ratio of 14.50, a price-to-earnings-growth ratio of 0.37 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $79.50. The company’s fifty day moving average price is $67.34 and its two-hundred day moving average price is $65.49.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company’s revenue was up 22.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.27 EPS. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.